📊 CV Key Takeaways
Is CapsoVision, Inc (CV) a Good Investment?
CapsoVision is a financially distressed medical device company with severe operational losses that far exceed revenues, negative free cash flow of -$15.3M, and deteriorating profitability. Despite healthy balance sheet liquidity metrics, the company is burning cash at an unsustainable rate with operating losses exceeding 180% of revenue, indicating fundamental business model challenges or failed commercialization efforts.
CapsoVision’s fundamentals are weak: a small revenue base is paired with extreme operating and net losses, and free cash flow is deeply negative relative to sales. The balance sheet is clean and liquid with no meaningful leverage, but current financial performance suggests the business model is not yet operating at a sustainable scale.
Why Buy CapsoVision, Inc Stock? CV Key Strengths
- Solid current ratio of 5.19x and quick ratio of 4.50x indicating near-term liquidity is not an immediate concern
- Gross margin of 54.2% suggests products have reasonable unit economics when sold
- Minimal debt burden with 0.00x debt-to-equity ratio providing some financial flexibility
- Strong liquidity with a 5.19x current ratio and 4.50x quick ratio
- No meaningful leverage, with debt/equity at 0.00x
- Healthy gross margin of 54.2%, indicating underlying product-level economics may be viable if operating expenses are controlled
CV Stock Risks: CapsoVision, Inc Investment Risks
- Severe operating losses of -$18.1M on only $9.6M revenue demonstrates inability to control operating expenses or achieve necessary scale
- Negative free cash flow of -$15.3M annually is unsustainable and indicates ongoing cash burn that will deplete equity reserves
- Negative net margin of -186% and negative ROE of -87.7% reveal fundamental unprofitability with no clear path to breakeven
- Operating cash flow of -$15.2M mirrors free cash flow, indicating losses are actual cash outflows not accounting adjustments
- Operating margin of -187.3% shows severe cost imbalance versus revenue
- Negative operating cash flow and free cash flow indicate ongoing cash burn
- Very weak returns on equity and assets suggest poor capital efficiency and limited evidence of scalable profitability
Key Metrics to Watch
- Revenue growth rate and ability to reach scale that justifies current operating cost structure
- Operating expense reduction initiatives and timeline to operating break-even
- Quarterly cash burn rate and cash runway remaining before liquidity crisis
- Gross margin trends to confirm products remain economically viable
- Operating cash flow and free cash flow burn rate
- Revenue growth relative to operating expense growth
CapsoVision, Inc (CV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.19x current ratio provides a solid financial cushion.
CV Profit Margin, ROE & Profitability Analysis
CV vs Healthcare Sector: How CapsoVision, Inc Compares
How CapsoVision, Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CapsoVision, Inc Stock Overvalued? CV Valuation Analysis 2026
Based on fundamental analysis, CapsoVision, Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CapsoVision, Inc Balance Sheet: CV Debt, Cash & Liquidity
CV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CapsoVision, Inc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-9.85 indicates the company is currently unprofitable.
CV Revenue Growth, EPS Growth & YoY Performance
CV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.0M | -$4.2M | $-0.17 |
| Q2 2025 | $2.8M | -$4.2M | $-2.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CapsoVision, Inc Dividends, Buybacks & Capital Allocation
CV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CapsoVision, Inc (CIK: 0001378325)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CV
What is the AI rating for CV?
CapsoVision, Inc (CV) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CV's key strengths?
Claude: Solid current ratio of 5.19x and quick ratio of 4.50x indicating near-term liquidity is not an immediate concern. Gross margin of 54.2% suggests products have reasonable unit economics when sold. ChatGPT: Strong liquidity with a 5.19x current ratio and 4.50x quick ratio. No meaningful leverage, with debt/equity at 0.00x.
What are the risks of investing in CV?
Claude: Severe operating losses of -$18.1M on only $9.6M revenue demonstrates inability to control operating expenses or achieve necessary scale. Negative free cash flow of -$15.3M annually is unsustainable and indicates ongoing cash burn that will deplete equity reserves. ChatGPT: Operating margin of -187.3% shows severe cost imbalance versus revenue. Negative operating cash flow and free cash flow indicate ongoing cash burn.
What is CV's revenue and growth?
CapsoVision, Inc reported revenue of $9.6M.
Does CV pay dividends?
CapsoVision, Inc does not currently pay dividends.
Where can I find CV SEC filings?
Official SEC filings for CapsoVision, Inc (CIK: 0001378325) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CV's EPS?
CapsoVision, Inc has a diluted EPS of $-1.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, CapsoVision, Inc has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CV stock overvalued or undervalued?
Valuation metrics for CV: ROE of -87.7% (sector avg: 15%), net margin of -186.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CV stock in 2026?
Our dual AI analysis gives CapsoVision, Inc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CV's free cash flow?
CapsoVision, Inc's operating cash flow is $-15.2M, with capital expenditures of $82.0K. FCF margin is -158.4%.
How does CV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -186.0% (avg: 12%), ROE -87.7% (avg: 15%), current ratio 5.19 (avg: 2).